Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Jan

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer

Treatment De-escalation in HPV-Associated Oropharyngeal Cancer Using Primary Radiotherapy vs Transoral Surgery

Gabapentin May Be an Effective Alternative to Opioids for Patients With Head and Neck Cancer Receiving Radiation

Role of Combined Positive Score With Treatment Outcomes in Recurrent or Metastatic Head and Neck Cancer

Study Finds Black and Hispanic Men With Throat Cancer Are Experiencing Higher Mortality White Men Are Increasingly Being Diagnosed at a Late Stage